Abstract
Since the histamine-3 receptor (H3R) was cloned in 1999, huge efforts have been made by most of the key players in the pharmaceutical industry as well as in smaller biotech companies to increase the knowledge on this peculiar receptor, with the ultimate goal of bringing new drugs to the market. This review gives a survey on the most valuable chemical tools discovered so far and the significant pharmacological experiments on metabolic disease models published to date. Pharmacology of H3R antagonists turns out to be very complex due to various functional activities, species selectivity, presence of H3R isoforms and the poorly understood dichotomy in efficacy between CNS and metabolic disease models. Adding an extra layer of complexity, researchers have to cope with some recurrent safety concerns, some of them being tightly linked to the nature of the H3R pharmacophore. Therefore this review also strives to summarize the major hurdles and some of the contradictions seen in the H3R field, together with a brief overview of the clinical trials currently running.
Keywords: Obesity, metabolic diseases, histamine-3, inverse agonist, protean agonist, safety, pharmacophore model, clinical trials, H3R, complex, dichotomy in efficacy, prevalence of obesity, Thrifty Genes Hypothesis, fat mass, hyperglycemia
Current Topics in Medicinal Chemistry
Title: The Histamine H3 Receptor as a Therapeutic Drug Target for Metabolic Disorders: Status, Challenges and Opportunities
Volume: 11 Issue: 12
Author(s): Jean-Marc Plancher
Affiliation:
Keywords: Obesity, metabolic diseases, histamine-3, inverse agonist, protean agonist, safety, pharmacophore model, clinical trials, H3R, complex, dichotomy in efficacy, prevalence of obesity, Thrifty Genes Hypothesis, fat mass, hyperglycemia
Abstract: Since the histamine-3 receptor (H3R) was cloned in 1999, huge efforts have been made by most of the key players in the pharmaceutical industry as well as in smaller biotech companies to increase the knowledge on this peculiar receptor, with the ultimate goal of bringing new drugs to the market. This review gives a survey on the most valuable chemical tools discovered so far and the significant pharmacological experiments on metabolic disease models published to date. Pharmacology of H3R antagonists turns out to be very complex due to various functional activities, species selectivity, presence of H3R isoforms and the poorly understood dichotomy in efficacy between CNS and metabolic disease models. Adding an extra layer of complexity, researchers have to cope with some recurrent safety concerns, some of them being tightly linked to the nature of the H3R pharmacophore. Therefore this review also strives to summarize the major hurdles and some of the contradictions seen in the H3R field, together with a brief overview of the clinical trials currently running.
Export Options
About this article
Cite this article as:
Plancher Jean-Marc, The Histamine H3 Receptor as a Therapeutic Drug Target for Metabolic Disorders: Status, Challenges and Opportunities, Current Topics in Medicinal Chemistry 2011; 11 (12) . https://dx.doi.org/10.2174/156802611795860906
DOI https://dx.doi.org/10.2174/156802611795860906 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The JPJDF has Synergistic Effect with Fluoropyrimidine in the Maintenance Therapy for Metastatic Colorectal Cancer
Recent Patents on Anti-Cancer Drug Discovery The Role of Catecholamines in Formation and Resolution of Pulmonary Oedema
Cardiovascular & Hematological Disorders-Drug Targets Cardiac Complications Attributed to Hydroxychloroquine: A Systematic Review of the Literature Pre-COVID-19
Current Cardiology Reviews Ligand Based Validated Comparative Chemometric Modeling and Pharmacophore Mapping of Aurone Derivatives as Antimalarial Agents
Current Computer-Aided Drug Design Platelet Function and Antiplatelet Therapy in Cardiovascular Disease: Implications of Genetic Polymorphisms
Current Vascular Pharmacology Oxidative Stress, Inflammation and Endothelial Biomarkers in Arterial Hypertension
Current Hypertension Reviews Insulin Resistance, Small LDL Particles, and Risk for Atherosclerotic Disease
Current Vascular Pharmacology Testosterone as Potential Effective Therapy in Treatment of Obesity in Men with Testosterone Deficiency: A Review
Current Diabetes Reviews Chemotherapeutic Options for Colorectal Cancer Patients with Cardiovascular Diseases.
Reviews on Recent Clinical Trials Long Term Treatment with Tetradecylthioacetic Acid Improves the Antioxidant Status in Obese Zucker (fa/fa) Rats
Drug Metabolism Letters Are the Myokines the Mediators of Physical Activity-Induced Health Benefits?
Current Pharmaceutical Design Respiratory Gas Exchange During Exercise in Children with Congenital Heart Disease: Methodology and Clinical Concepts
Current Respiratory Medicine Reviews The Role of Stem Cell Factor and Granulocyte-Colony Stimulating Factor in Treatment of Stroke
Recent Patents on CNS Drug Discovery (Discontinued) Oral Infection and Vascular Disease
Vascular Disease Prevention (Discontinued) Beta-arrestin Biased Agonism/Antagonism at Cardiovascular Seven Transmembrane-spanning Receptors
Current Pharmaceutical Design Sirolimus: A Novel Immunosuppressive Drug in Heart Transplantation
Recent Patents on Cardiovascular Drug Discovery Hypertension and Endothelial Dysfunction: Therapeutic Approach
Current Vascular Pharmacology The Association of Palmitoylethanolamide with Luteolin Decreases Neuroinflammation and Stimulates Autophagy in Parkinson's Disease Model
CNS & Neurological Disorders - Drug Targets GH Supplementation Effects on Cardiovascular Risk in GH Deficient Adult Patients: A Systematic Review and Meta-analysis
Endocrine, Metabolic & Immune Disorders - Drug Targets Cardiac Oxidative Stress and Inflammation are Similar in SAMP8 and SAMR1 Mice and Unaltered by Curcumin and Ginkgo biloba Extract Intake
Current Pharmaceutical Biotechnology